Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Change in Visceral Adiposity |
Visceral fat content measured using a dual energy x-ray absorptiometry (DXA) scanner |
Change from Baseline Visceral Adiposity at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Height (cm) |
Height measured with standardized method |
At baseline |
|
Secondary |
Age |
The age of the volunteers will be recorded in the case report form. |
At day -7 (pre-selection visit) |
|
Secondary |
Ethnicity |
The ethnicity of the volunteers will be recorded in the case report form. |
At day -7 (pre-selection visit) |
|
Secondary |
Change in Body Weight (kg) |
Weight measured with standardized method |
Change from Baseline Weight at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Body Mass Index (BMI) (Kg/m^2) |
Weight and height will be combined to report BMI in kg/m^2 |
Change from Baseline Body Mass Index at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Neck circumference (cm) |
Neck circumference using a measuring tape |
Change from Baseline Neck circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Arm circumference (cm) |
Arm circumference using a measuring tape |
Change from Baseline Arm circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Waist circumference (cm) |
Waist circumference using a measuring tape |
Change from Baseline Waist circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Hip circumference (cm) |
Hip circumference using a measuring tape |
Change from Baseline hip circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Conicity Index |
Weight, height and waist circumference will be combined to report Conicity index. |
Change from Baseline Conicity Index at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Waist-to-Hip ratio |
Waist and Hip circumference will be combined to report Waist-to-Hip ratio |
Change from Baseline Waist-to-Hip ratio at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Lipid Accumulation Product (LAP) |
Waist circumference and fasting plasma Triglycerides will be combined to report Lipid Accumulation Product |
Change from Baseline Lipid Accumulation Product ratio at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Systolic Blood Pressure (mm Hg) |
Systolic blood pressure will be measured using an automatic sphygmomanometer |
Change from Baseline Systolic Blood Pressure at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Diastolic Blood Pressure (mm Hg) |
Diastolic blood pressure will be measured using an automatic sphygmomanometer |
Change from Baseline Systolic Blood Pressure at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in heart rate (bpm) |
Heart rate will be measured using an automatic sphygmomanometer |
Change from Baseline Heart rate at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum glucose levels (mg/dL) |
Serum glucose levels will be determined by standardized spectrophotometry methods |
Change from Baseline serum glucose levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum total cholesterol (mg/dL) |
Total cholesterol will be determined by standardized spectrophotometry methods |
Change from Baseline serum total cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum high-density lipoprotein cholesterol (HDL-C,mg/dL) |
High-density lipoprotein cholesterol will be determined by standardized spectrophotometry methods |
Change from Baseline serum high-density lipoprotein cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum low-density lipoprotein cholesterol (LDL-C, mg/dL) |
Low-density lipoprotein cholesterol will be calculated using the Friedewald formula |
Change from Baseline serum low-density lipoprotein cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum triglycerides (TG, mg/dL) |
Triglycerides will be determined by standardized spectrophotometry methods |
Change from Baseline serum triglycerides at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum alanine aminotransferase (ALT, U/L) |
Alanine aminotransferase will be determined by standardized spectrophotometry methods |
Change from Baseline serum alanine aminotransferase at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum aspartate aminotransferase (AST, U/L) |
Aspartate aminotransferase will be determined by standardized spectrophotometry methods |
Change from Baseline serum aspartate aminotransferase at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum gamma glutamyl transferase (GGT, U/L) |
Gamma glutamyl transferase will be determined by standardized spectrophotometry methods |
Change from Baseline serum gamma glutamyl transferase at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum insulin levels (mU/L) |
Insulin levels will be measured by standardized chemiluminescence methods. |
Change from Baseline serum insulin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum leptin levels (pg/mL) |
Leptin levels will be measured by standardized chemiluminescence methods |
Change from Baseline serum leptin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum adiponectin levels (ng/mL) |
Adiponectin levels will be measured by standardized chemiluminescence methods |
Change from Baseline serum adiponectin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Adiponectin/Leptin ratio (numerical ratio) |
Adiponectin and leptin will be combined to report adiponectin/leptin ratio |
Change from Baseline Adiponectin/Leptin ratio at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum Monocyte chemoattractant protein-1 (MCP-1) levels (pg/mL) |
MCP-1 levels will be measured by standardized chemiluminescence methods |
Change from Baseline serum MCP-1 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma tumor necrosis factor alpha (TNF-alpha) levels (pg/mL) |
TNF-alpha levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma TNF-alpha levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma Interleukin 6 (IL-6) levels (pg/mL) |
IL-6 levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma IL-6 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma Interleukin 10 (IL-10) levels (pg/mL) |
IL-10 levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma IL-10 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma Intercellular Adhesion Molecule 1 (ICAM-1) levels (ng/mL) |
ICAM-1 levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma ICAM-1 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma Cluster of Differentiation 14 (CD14) levels (pg/mL) |
CD14 levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma CD14 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in plasma oxidized low density lipoproteins (LDLox) levels (mU/L) |
LDLox levels will be measured by standardized chemiluminescence methods |
Change from Baseline plasma LDLox levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in serum C-Reactive protein levels (mg/L) |
C-Reactive protein levels will be determined by standardized spectrophotometry methods |
Change from Baseline serum C-Reactive protein levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Histidine levels in blood (umol/L) |
Serum histidine levels will be determined by Liquid Chromatography coupled to tandem Mass Spectrometry |
Change from Baseline Histidine levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Acylcarnitine levels in blood (umol/L) |
Serum Acylcarnitine levels will be determined by Liquid Chromatography coupled to tandem Mass Spectrometry |
Change from Baseline Acylcarnitine levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in 17-beta-estradiol (E2) levels in blood (pg/mL) |
Serum 17-beta-estradiol (E2) levels will be determined by standardized chemiluminescence methods |
Change from Baseline 17-beta-estradiol (E2) levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Follicle-stimulating hormone (FSH) levels in blood (mU/mL) |
Follicle-stimulating hormone (FSH) levels will be determined by standardized chemiluminescence methods |
Change from Baseline FSH levels at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR) |
HOMA-IR will be calculated using serum glucose and insulin levels. |
Change from Baseline HOMA-IR at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Fatty Liver Index (FLI) |
FLI will be calculated using BMI, waist circumference, serum triglycerides and gamma glutamyl transferase levels |
Change from Baseline FLI at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Triglyceride glucose index (TyG) |
TyG will be calculated using serum glucose and triglycerides levels |
Change from Baseline TyG at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Plasma atherogenic index |
Plasma atherogenic index will be calculated as the logarithm of the TG to HDL-c ratio |
Change from Baseline Plasma atherogenic index at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in lipidomic profile |
Lipidomic analyses will be done by Liquid Chromatography coupled to tandem Mass Spectrometry |
Change from Baseline Lipidomic profile at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in intestinal microbiota composition |
Metagenomic analysis in fecal samples. The bacteria DNA will be extracted and massive sequenced by the Ion Torrent platform. |
Change from Baseline intestinal microbiota composition at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in the expression of lipid-metabolism genes in PBMC |
Peripheral blood mononuclear cell (PBMC) will be isolated to obtain the RNA for gene expression analyses by Quantitative reverse transcription PCR (RT-qPCR) |
Change from Baseline gene expression at 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Dietary habits |
Nutritional habits will be determined based on the results obtained from the 3-day dietary record |
Change from Baseline Dietary habits at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in Physical activity |
Physical activity will be evaluated through the International Physical Activity Questionnaire (IPAQ)-short for physical activity questionnaire. Scores will be reported in categories: LOW activity levels, MODERATE activity levels or HIGH activity levels with the latter indicating better outcomes. |
Change from Baseline Physical activity at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Concomitant medication |
Concomitant medication consumed during the study will be recorded in the case report form. |
At day -7 (pre-selection visit), day 1 (visit V1), day 43 (visit 2) and day 85 (visit 3) |
|
Secondary |
Consumption of dietary supplements |
Dietary supplements consumed during the study will be recorded in the case report form. |
At day -7 (pre-selection visit), day 1 (visit V1), day 43 (visit 2) and day 85 (visit 3) |
|
Secondary |
Change in the Supraclavicular skin temperature |
Supraclavicular skin temperature will be measured with the FLIR T530 thermal imaging camera |
Change from Baseline Supraclavicular skin temperature at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Change in postmenopausal symptoms |
Postmenopausal symptoms will be evaluated through the Menopause Rating Scale (MRS) questionnaire. The MRS comprises 11 items representing various symptoms or complaints. Each symptom can be rated from 0 (indicating no complaints) to 4 points (indicating severe symptoms), depending on the perceived severity reported by the women completing the scale. The total MRS score ranges from 0 (asymptomatic) to 44 (maximum complaint severity). |
Change from Baseline postmenopausal symptoms at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo) |
|
Secondary |
Adverse events |
Possible adverse events derived from taking study's products will be recorded in the case report form |
At 6 weeks (V2) and at 12 weeks (V3) for each of the two treatments (multi-ingredient and placebo) |
|